Biognosys Launches New Plasma Proteomics Solution P2-iST and OmicsFlow Platform, and Announces the Formation of Biognosys Group
November 10, 2025 – TORONTO, Canada. Biognosys Group, a global leader in mass spectrometry-based multiomics solutions, today announced the launch of the P2-iST Plasma solution and OmicsFlow® platform at the HUPO World Conference, taking place November 9–13 in Toronto, Canada.
Formation of the Biognosys Group
Biognosys has become part of the newly established Biognosys Group, an affiliate of Bruker. The Biognosys Group delivers high-performance, robust solutions across proteomics, metabolomics, and lipidomics, driving innovation at the forefront of multiomics. Building on the combined strengths of PreOmics, Biognosys, and biocrates, the Group develops and commercializes industry-leading consumables, software, instruments, and CRO services to make advanced mass spectrometry workflows seamless, scalable, and accessible to every laboratory. Maintaining a vendor-neutral position, Biognosys Group ensures broad compatibility of its solutions with all major mass spectrometry platforms. Designed for agility, the Group’s solutions can operate independently or as part of a unified ecosystem, supported by flexible business models and a strong commitment to partnership.
Launch of P2-iST Plasma Solution
The Biognosys Group has launched the P2-iST Plasma solution, a next-generation technology that unites the proven performance of Biognosys’ P2 Plasma Enrichment with the robustness of PreOmics’ iST technology. This innovative nanoparticle-based plasma workflow delivers unprecedented proteome depth, identifying nearly 6,000 proteins with >90% data completeness across a pilot study of 12 cancer and healthy plasma samples. Benchmarking studies further demonstrate its exceptional quantitative precision, setting a new standard for plasma proteomics performance.
Built for scalability and efficiency, the P2-iST Plasma solution allows processing of up to 192 samples per day using standard automation platforms, providing a flexible, cost-effective, and highly reliable solution for a wide range of research applications.
Designed for seamless integration into any laboratory environment, the P2-iST Plasma solution is available through flexible business models, ranging from research-use kits to dedicated CRO services. The technology is currently offered under Early Access, including comprehensive method transfer and implementation support for selected expert laboratories.
Launch of OmicsFlow® Platform
Biognosys Group is also expanding its proteomics software suite with the launch of OmicsFlow, a fast, scalable, and user-friendly platform for orchestrating and parallelizing omics data analysis. OmicsFlow enables streamlined deployment in the cloud environment, empowering researchers with flexibility, scalability, and performance to accelerate data-driven discoveries.
Biognosys Group at HUPO 2025
At HUPO 2025, Biognosys Group will present groundbreaking innovations in proteomics, featuring three oral presentations focused on biomarker discovery using P2 Enrichment Technology in plasma and cerebrospinal fluid, advancing research in cancer and neurodegenerative diseases.
During a breakfast seminar entitled “Expert Solutions for Real-World Research Challenges,” industry and academic experts will showcase the latest advances in mass spectrometry–based plasma proteomics and immunopeptidomics, highlighting how Biognosys Group’s technologies are enabling deeper biological insights and translational discoveries.
In addition, Biognosys Group will present 16 scientific posters spanning its proteomics consumables, software, and CRO solutions, demonstrating breakthroughs in immunopeptidomics, automation for large-scale degrader screening, and its Digital Proteome — a multi-species, multi-tissue proteome expression atlas. Further highlights include advancements in host cell protein quantification and FFPE sample profiling using PreOmics’ BeatBox®.
Join Biognosys Group at Booths #703 and #803 at HUPO 2025 to explore how its cutting-edge proteomics solutions are driving the new frontier of biomarker discovery and translational research.